Breaking News on Global Pharmaceutical Technology & Manufacturing

News in brief

Hospira takeover of Orchid’s injectables to complete in March

17-Feb-2010

Related topics: Delivery technologies, Ingredients, Mergers and acquisitions

Hospira’s acquisition of Orchid Chemicals and Pharmaceuticals generic injectables business is on track to complete next month now the Hart-Scott-Rodino period required by the US Federal Trade Commission has elapsed.

The $400m (€278m) deal, announced in December , adds Orchid’s US Food and Drug Administration (FDA) approved injectables facility in Chennai, India to Hospira’s global manufacturing network.

CEO Christopher Begley said: "Orchid's capabilities provide a platform for future commercial growth, and we look forward to welcoming our new employees, whose talents and skill sets will contribute to Hospira's success."

The deal will also see Orchid supply Hospira with active pharmaceutical ingredients (APIs) under a long-term agreement.

Copyright - Unless otherwise stated all contents of this web site are © 2012 - William Reed Business Media SAS - All Rights Reserved - For permission to reproduce any contents of this web site, please email our Syndication department copyright@wrbm.com - Full details for the use of materials on this site can be found in the Terms & Conditions

© 2012 - William Reed Business Media SAS - All rights reserved.